Neuronal life span versus health span: Principles of natural selection at work in the degenerating brain

Journal of Molecular Neuroscience

Volumn 45, Issue 3, 2011, Pages 467-472

  O'Leary III, John C ^a   Koren III, John ^a   Dickey, Chad A ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Alzheimer's; Neurodegeneration; Neuroprotection; Solubility; Tau

Indexed keywords

ALPHA TOCOPHEROL; INDOLEPROPIONIC ACID; RESVERATROL; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN BLOOD FLOW; CELL SURVIVAL; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; MEMORY; MOLECULAR PATHOLOGY; NATURAL SELECTION; NERVE DEGENERATION; NERVE FUNCTION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN;

ALZHEIMER DISEASE; ANIMALS; BRAIN; CELL SURVIVAL; CEREBROVASCULAR CIRCULATION; HUMANS; NEURONS; NEUROPROTECTIVE AGENTS; SELECTION, GENETIC; TAU PROTEINS;

EID: 80855131568     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-011-9540-4     Document Type: Conference Paper

References (44)

1. JF Abisambra LJ Blair SE Hill, et al. 2010 Phosphorylation dynamics regulate Hsp27-mediated rescue of neuronal plasticity deficits in tau transgenic mice J Neurosci 30 15374 15382 21084594 10.1523/JNEUROSCI.3155-10.2010 1:CAS:528:DC%2BC3cXhsFWitbzI
2. D Albani L Polito A Signorini G Forloni 2010 Neuroprotective properties of resveratrol in different neurodegenerative disorders Biofactors 36 370 376 20848560 10.1002/biof.118 1:CAS:528:DC%2BC3cXhtl2msLjO
3. C Andorfer Y Kress M Espinoza, et al. 2003 Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms J Neurochem 86 582 590 12859672 10.1046/j.1471-4159.2003.01879.x 1:CAS:528:DC%2BD3sXlvF2ntbs%3D
4. RD Bell R Deane N Chow, et al. 2009 SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells Nat Cell Biol 11 143 153 19098903 10.1038/ncb1819 1:CAS:528:DC%2BD1MXht1Oqt7g%3D
5. GJ Brewer 2010 Why vitamin E therapy fails for treatment of Alzheimer's disease J Alzheimers Dis 19 27 30 20061623
6. N Chow RD Bell R Deane, et al. 2007 Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype Proc Natl Acad Sci USA 104 823 828 17215356 10.1073/pnas.0608251104 1:CAS:528:DC%2BD2sXhtVegtr0%3D
7. R Dayanandan M Van Slegtenhorst TG Mack, et al. 1999 Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation FEBS Lett 446 228 232 10100846 10.1016/S0014-5793(99)00222-7 1:CAS:528:DyaK1MXhvVCmtLw%3D
8. A de Calignon LM Fox R Pitstick, et al. 2010 Caspase activation precedes and leads to tangles Nature 26 787 789
9. J Ghiso E Matsubara A Koudinov, et al. 1993 The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex Biochem J 293 Pt 1 27 30 8328966 1:CAS:528:DyaK3sXks12lsb8%3D
10. M Grundman 2000 Vitamin E and Alzheimer disease: the basis for additional clinical trials Am J Clin Nutr 71 630S 636S 10681271 1:STN:280: DC%2BD3c7kt1Onsg%3D%3D
11. A Harada K Oguchi S Okabe, et al. 1994 Altered microtubule organization in small-calibre axons of mice lacking tau protein Nature 369 488 491 8202139 10.1038/369488a0 1:CAS:528:DyaK2cXksl2nsLY%3D
12. IK Hwang KY Yoo H Li, et al. 2009 Indole-3-propionic acid attenuates neuronal damage and oxidative stress in the ischemic hippocampus J Neurosci Res 87 2126 2137 19235887 10.1002/jnr.22030 1:CAS:528:DC%2BD1MXlvV2rt70%3D
13. C Iadecola 2004 Neurovascular regulation in the normal brain and in Alzheimer's disease Nat Rev Neurosci 5 347 360 15100718 10.1038/nrn1387 1:CAS:528:DC%2BD2cXjt1ClsLY%3D
14. LM Ittner YD Ke F Delerue, et al. 2010 Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models Cell 142 387 397 20655099 10.1016/j.cell.2010.06.036 1:CAS:528:DC%2BC3cXpvFKrtr4%3D
15. UK Jinwal Y Miyata J Koren 3rd, et al. 2009 Chemical manipulation of hsp70 ATPase activity regulates tau stability J Neurosci 29 12079 12088 19793966 10.1523/JNEUROSCI.3345-09.2009 1:CAS:528:DC%2BD1MXht12qu7zN
16. SS Karuppagounder JT Pinto H Xu HL Chen MF Beal GE Gibson 2009 Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease Neurochem Int 54 111 118 19041676 10.1016/j.neuint.2008. 10.008 1:CAS:528:DC%2BD1MXit1Krt7Y%3D
17. D Kim MD Nguyen MM Dobbin, et al. 2007 SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis EMBO J 26 3169 3179 17581637 10.1038/sj.emboj.7601758 1:CAS:528:DC%2BD2sXnsFejt7k%3D
18. T Kimura T Fukuda N Sahara, et al. 2010 Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss J Biol Chem 285 38692 38699 20921222 10.1074/jbc.M110.136630 1:CAS:528: DC%2BC3cXhsVOku7nP
19. ME King HM Kan PW Baas A Erisir CG Glabe GS Bloom 2006 Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid J Cell Biol 175 541 546 17101697 10.1083/jcb.200605187 1:CAS:528:DC%2BD28Xht1GksbvK
20. E Matsubara J Ghiso B Frangione, et al. 1999 Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome Ann Neurol 45 537 541 10211483 10.1002/1531-8249(199904)45:4<537::AID-ANA20>3.0.CO;2-2 1:STN:280:DyaK1M3is1Cltw%3D%3D
21. DX Medina A Caccamo S Oddo 2011 Methylene blue reduces abeta levels and rescues early cognitive deficit by increasing proteasome activity Brain Pathol 21 2 140 149 20731659 10.1111/j.1750-3639.2010.00430.x 1:CAS:528: DC%2BC3MXls1Cis74%3D
22. D Morshedi N Rezaei-Ghaleh A Ebrahim-Habibi S Ahmadian M Nemat-Gorgani 2007 Inhibition of amyloid fibrillation of lysozyme by indole derivatives-possible mechanism of action FEBS J 274 6415 6425 18028426 1:CAS:528:DC%2BD2sXhsVOnsrbF
23. K Niwa L Younkin C Ebeling, et al. 2000 Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation Proc Natl Acad Sci USA 97 9735 9740 10944232 10.1073/pnas.97.17.9735 1:CAS:528:DC%2BD3cXmtVentLs%3D
24. K Niwa VA Porter K Kazama D Cornfield GA Carlson C Iadecola 2001 A beta-peptides enhance vasoconstriction in cerebral circulation Am J Physiol Heart Circ Physiol 281 H2417 H2424 11709407 1:CAS:528:DC%2BD3MXptlKgu7Y%3D
25. T O'Connor KR Sadleir E Maus, et al. 2008 Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis Neuron 60 988 1009 19109907 10.1016/j.neuron.2008.10.047
26. JC O'Leary 3rd Q Li P Marinec, et al. 2010 Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden Mol Neurodegener 5 45 21040568 10.1186/1750-1326-5-45
27. D Paris KP Townsend J Humphrey DF Obregon K Yokota M Mullan 2002 Statins inhibit A beta-neurotoxicity in vitro and A beta-induced vasoconstriction and inflammation in rat aortae Atherosclerosis 161 293 299 11888511 10.1016/S0021-9150(01)00660-8 1:CAS:528:DC%2BD38XhvVWksLY%3D
28. RC Petersen RG Thomas M Grundman, et al. 2005 Vitamin E and donepezil for the treatment of mild cognitive impairment N Engl J Med 352 2379 2388 15829527 10.1056/NEJMoa050151 1:CAS:528:DC%2BD2MXltVCjsbg%3D
29. M Rapoport HN Dawson LI Binder MP Vitek A Ferreira 2002 Tau is essential to beta-amyloid-induced neurotoxicity Proc Natl Acad Sci USA 99 6364 6369 11959919 10.1073/pnas.092136199 1:CAS:528:DC%2BD38XjslWnt74%3D
30. JM Redwine B Kosofsky RE Jacobs, et al. 2003 Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis Proc Natl Acad Sci USA 100 1381 1386 12552120 10.1073/pnas.242746599 1:CAS:528:DC%2BD3sXhtF2gu7k%3D
31. ED Roberson K Scearce-Levie JJ Palop, et al. 2007 Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model Science 316 750 754 17478722 10.1126/science.1141736 1:CAS:528: DC%2BD2sXkvVWrtrw%3D
32. K Santacruz J Lewis T Spires, et al. 2005 Tau suppression in a neurodegenerative mouse model improves memory function Science 309 476 481 16020737 10.1126/science.1113694 1:CAS:528:DC%2BD2MXmtVersLc%3D
33. AL Schwarzman L Gregori MP Vitek, et al. 1994 Transthyretin sequesters amyloid beta protein and prevents amyloid formation Proc Natl Acad Sci USA 91 8368 8372 8078889 10.1073/pnas.91.18.8368 1:CAS:528:DyaK2cXlslKktLk%3D
34. M Shibata S Yamada SR Kumar, et al. 2000 Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier J Clin Invest 106 1489 1499 11120756 10.1172/JCI10498 1:CAS:528:DC%2BD3cXovFagtbs%3D
35. J Simon-Sanchez C Schulte JM Bras, et al. 2009 Genome-wide association study reveals genetic risk underlying Parkinson's disease Nat Genet 41 1308 1312 19915575 10.1038/ng.487 1:CAS:528:DC%2BD1MXhsVWlsbrP
36. KL Tucker M Meyer YA Barde 2001 Neurotrophins are required for nerve growth during development Nat Neurosci 4 29 37 11135642 10.1038/82868 1:CAS:528:DC%2BD3MXitVegsQ%3D%3D
37. B Urmoneit I Prikulis G Wihl, et al. 1997 Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy Lab Invest 77 157 166 9274858 1:CAS:528:DyaK2sXlvFeisL4%3D
38. U Wagner M Utton JM Gallo CC Miller 1996 Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation J Cell Sci 109 Pt 6 1537 1543 8799840 1:CAS:528:DyaK28XktValsrk%3D
39. J Wang L Ho Z Zhao, et al. 2006 Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease FASEB J 20 2313 2320 17077308 10.1096/fj.06-6281com 1:CAS:528: DC%2BD28XhtFylsrnL
40. C Wischik R Staff 2009 Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy J Nutr Health Aging 13 367 369 19300883 10.1007/s12603-009- 0046-5 1:STN:280:DC%2BD1M3it1WgtQ%3D%3D
41. CM Wischik PC Edwards RY Lai M Roth CR Harrington 1996 Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines Proc Natl Acad Sci USA 93 11213 11218 8855335 10.1073/pnas.93.20.11213 1:CAS:528:DyaK28XmtVOqsLg%3D
42. DS Yang JD Smith Z Zhou SE Gandy RN Martins 1997 Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma J Neurochem 68 721 725 9003062 10.1046/j.1471-4159.1997.68020721.x 1:CAS:528:DyaK2sXot1yktA%3D%3D
43. A Yuan A Kumar C Peterhoff K Duff RA Nixon 2008 Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice J Neurosci 28 1682 1687 18272688 10.1523/JNEUROSCI.5242-07.2008 1:CAS:528:DC%2BD1cXnvVSrt7s%3D
44. BV Zlokovic 2008 The blood-brain barrier in health and chronic neurodegenerative disorders Neuron 57 178 201 18215617 10.1016/j.neuron.2008.01. 003 1:CAS:528:DC%2BD1cXhvVSrtrc%3D